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Mitochondrial-derived reactive oxygen species have been deemed an important contributor in sepsis pathogenesis. We investigated
whether two mitochondria-targeted antioxidants (mtAOX; SkQ1 and MitoTEMPO) improved long-term outcome, lessened
inﬂammation, and improved organ homeostasis in polymicrobial murine sepsis. 3-month-old female CD-1 mice (n = 90)
underwent cecal ligation and puncture (CLP) and received SkQ1 (5 nmol/kg), MitoTEMPO (50 nmol/kg), or vehicle 5 times
post-CLP. Separately, 52 SkQ1-treated CLP mice were sacriﬁced at 24 h and 48 h for additional endpoints. Neither MitoTEMPO
nor SkQ1 exerted any protracted survival beneﬁt. Conversely, SkQ1 exacerbated 28-day mortality by 29%. CLP induced release
of 10 circulating cytokines, increased urea, ALT, and LDH, and decreased glucose but irrespectively of treatment. Similar
occurred for CLP-induced lymphopenia/neutrophilia and the NO blood release. At 48 h post-CLP, dying mice had
approximately 100-fold more CFUs in the spleen than survivors, but this was not SkQ1 related. At 48 h, macrophage and
granulocyte counts increased in the peritoneal lavage but irrespectively of SkQ1. Similarly, hepatic mitophagy was not
altered by SkQ1 at 24 h. The absence of survival beneﬁt of mtAOX may be due to the extended treatment and/or a
relatively moderate-risk-of-death CLP cohort. Long-term eﬀect of mtAOX in abdominal sepsis appears diﬀerent to sepsis/
inﬂammation models arising from other body compartments.
1. Introduction
Sepsis is a deleterious clinical condition caused by a deregu-
lated host response to infection associated with organ dam-
age [1]. In immunocompetent individuals, sepsis provokes
a robust systemic inﬂammatory response (which can coexist
with concurrently developing immunosuppression). Various
microbial, fungal, or viral components in the invaded host
lead to a rapid, simultaneous release of pro- and anti-
inﬂammatory mediators [2] and general activation of the
innate/adaptive immunity. The acute phase of humoral and
cellular response is accompanied by a rapid production of
reactive oxygen species (ROS) [3]. Under physiological con-
ditions, ROS are produced by diﬀerent intra-/extracellular
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sources [4] with mitochondria as one of the main sites [5, 6].
Tightly regulated by cellular antioxidant mechanisms, at
low-to-moderate concentrations, ROS have potent beneﬁcial
eﬀects as an intrinsic part of various intracellular signaling
pathways [5, 7, 8]. In contrast, increased ROS concentration
(e.g., caused by depletion of regulatory antioxidants, inade-
quate antioxidative response [9], and/or altered ROS release)
can elicit a chain reaction cascade that can damage the cells
and tissues of the host [4]. This oxidative stress has been
considered as one of the key contributors to the development
of organ failure in sepsis and linked to a deregulation of
mitochondrial function [10–12].
Numerous preclinical studies demonstrated clear beneﬁts
of an antioxidant-dependent inhibition of ROS production/
release in diﬀerent pathophysiological conditions [13, 14]
including sepsis [15–19]. In contrast, clinical trials either
failed to show any survival beneﬁt in septic patients or were
inconclusive [20–22]. In general, the incompatibility between
preclinical and clinical studies (and among the clinical
studies themselves) is due to numerous reasons including
nonmatching models, erroneous study design, and/or non-
speciﬁc therapeutics. First, endotoxemia/LPS models are
now considered inappropriate in recapitulating human sepsis
syndromes [23]. Furthermore, due to a lack of clear dose-
limiting toxicities, the dosages used in clinical trials are typi-
cally selected based on an “appeared feasible” subjective
approach rather than preveriﬁed dose response studies [22].
For example, failure of a nonselective nitric oxide synthase
inhibitor (46C88; L-NMMA acronym) phase 3 trial (versus
phase 2) was partly attributed to the excessive L-NMMA dose
and suboptimal selection of septic patients [24, 25]. Equally
important is the element of therapeutic speciﬁcity: majority
of studies applied nonselective antioxidants such as selenium,
melatonin, ascorbic acid, n-acetylcystein, and α-tocopherol
whose actions may be simultaneously too wide ranging
and/or mistargeted.
Regarding the latter shortcoming, various conjugation
protocols were developed (e.g., with lipophilic cations) to
target the exogenous antioxidants directly to mitochondria.
The best characterized to date is triphenylphosphonium
(TPP) formulation [26]: it enables precise and uncorrupted
cross-membrane delivery of antioxidants [27, 28] and has
led to development of two very promising substances. SkQ1
is a novel, rechargeable plastoquinone derivative, which
accumulates in the inner mitochondrial membrane due
to its molecular charge and lipophilic properties [29, 30].
It shows antioxidant eﬀects at much lower concentrations
than other TPP conjugates, thus the “window” between
anti- and prooxidant eﬀects is larger [30]. MitoTEMPO is a
piperidine-based nitroxide that works as a hydrophilic
superoxide dismutase mimetic in the mitochondrial matrix.
Positive preclinical results of SkQ1 and MitoTEMPO in var-
ious diseases including CLP [13, 31–35] and their strong
immunomodulatory properties [36, 37] have been largely
attributed to their high-target speciﬁcity.
Until now, MitoTEMPO (as mitochondria-speciﬁc
ROS scavenger) was studied in the mouse CLP model
for only a short term [35]. However, sepsis causes severe
protracted sequelae and neither of those compounds has
ever been tested in a clinically relevant sepsis model for
their long-term eﬀects. Hence, in this study, we investi-
gated the inﬂuence of these two speciﬁc TPP-conjugated
ROS scavengers, SkQ1 and MitoTEMPO, upon inﬂamma-
tory response, organ function, and long-term outcome in a
mouse model of polymicrobial acute sepsis originating from
the abdominal compartment.
2. Materials and Methods
2.1. Animals. Female, 3-month-old, outbred CD-1 mice
(Charles River Laboratories; n = 142) were used for all exper-
iments (the exact n/group is speciﬁed in the legend to each
ﬁgure). The genetic diversity of the CD-1 outbred strain
(e.g., compared to BALB/c) is closer to patient diversity and
therefore clinically more relevant. We chose sexually mature,
healthy females to exclude confounding tangibles such as
comorbidities and young/old age and to follow on the NIH
recommendation to study females given their underrepresen-
tation in preclinical intensive care research. Experiments 1
and 2 were performed in Ludwig Boltzmann Institute for
Experimental and Clinical Traumatology (LBI), Vienna,
Austria, and experiment 3 was performed in Institute of
Surgical Research (ISR), University of Szeged, Faculty of
Medicine, Szeged, Hungary. All mice were allowed to
acclimatize to their new environment for at least one week
after arrival. Mice were housed on a 12h light-dark cycle
with controlled temperature (21–23°C) and provided with
standard rodent diet and water ad libitum.
2.2. Ethics Statement. All animal procedures were approved
by the Viennese (Austria) Legislative Committee (Animal
Use Proposal Permission number: 006596/2011/11) and
the Hungarian Scientiﬁc Ethical Committee on Animal
Experimentation (Animal Use Proposal Permission number:
V./148/2013) All experiments were conducted according to
the National Institutes of Health guidelines.
All mice were monitored by trained professionals at
least three times per day and more whenever an animal’s
condition deteriorated [38, 39]. In order to avoid unneces-
sary suﬀering of CLP mice facing imminent death, we use
in our laboratory a custom-developed scoring approach
that combines the mouse clinical assessment scoring system
(M-CASS) and sequential body temperature (BT) measure-
ments. In brief, well-being and general condition of mice
(i.e., fur, posture, mobility, alertness, weight, and startle
reﬂex) were assessed every 12 hours (starting 12 h post-
CLP), by assigning mice to one out of maximum three sever-
ity grades (i.e., 0, 1, or 2 points). Additionally, we measured
inner BT. Mice were euthanized once the score indicated
imminent death, that is, a score≥ 8 and/or inability to trigger
the startle reﬂex and/or BT< 28°C (recorded in at least two
sequential measurements; the score sheet in Supplementary
Figure 1 available online at https://doi.org/10.1155/2017/
6412682). This approach is generally in line with the recent
mouse M-CASS philosophy proposed by Lilley et al. [40].
The BT-based prediction of outcome we have developed in
our laboratory is very precise (AUC=0.94; [41]). Combina-
tion of the BT-based prediction with our custom-developed
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(M-CASS-like) scoring system prevents overliberal euthana-
sia decision-making, that is, allocation of potential survivors
to the P-DIE group in survival studies.
2.3. Sepsis Model. Mice were subjected to cecal ligation and
puncture (CLP) surgery according to the protocol by
Wichterman et al. [42] with modiﬁcations described else-
where [43]. We performed a medium severe CLP (18G
needle) to reach an approximately 40% mortality (i.e., by
day 28 post-CLP) that corresponds to mortality of human
patients suﬀering from abdominal sepsis [44, 45]. Brieﬂy,
after opening the abdominal cavity via midline laparot-
omy, the cecum was exposed, ligated, and punctured twice
(small amount of feces was extruded to ensure patency of the
punctures). After repositioning of the cecum, the abdomen
was closed with two single button sutures and Histoacryl®
skin adhesive. Starting 2 hours post-CLP, all mice received
subcutaneous broad-spectrum antibiotic therapy (25mg/kg
imipenem/cilastatin, Zienam®) and ﬂuid resuscitation (1ml
Ringer’s solution) with analgesia (0.05mg/kg buprenorphine,
Bupaq®) twice daily (in approx. 12 h intervals) for ﬁve con-
secutive days (experiment 1) or until the time point of eutha-
nasia (in experiments 2 and 3). Five-day course of antibiotic
coverage is routinely employed in CLP studies [46].
2.4. Study Design
2.4.1. CLP Experiments. The entire study was performed in
three separate experimental blocks: experiment 1 as the main
survival part (SkQ1 and MitoTEMPO; Figures 1, 2, 3, 4, and
5) and follow-up experiment 2 (SkQ1 only; Figures 6 and 7;
both in LBI) and experiment 3 (SkQ1 only; Figure 8; in
ISR). To maximize reliability and minimize random eﬀects
in experiment 1, we conducted CLP in small groups of 15
mice per repetition (6 repetitions in total). Moreover, irre-
spective of location, all CLP surgeries were performed by
the same operator (P.R.).
The follow-up experiments 2 and 3 had diﬀerent sacriﬁce
time points: at 48 h in experiment 2 and at 24h post-CLP in
experiment 3 (Figure 9 scheme). The time points were cho-
sen based on the investigated endpoints: 48 h time point for
bacterial load at the time of the maximal post-CLP mortality
(experiment 2) and 24 h time point for potential mitophagy;
the period closely preceding the most robust post-CLP deaths
(experiment 3).
To ensure similar CLP severity between LBI (experiments
1 and 2) and ISR (experiment 3), we used BT proﬁling, that
is, three (separate) pilot CLP runs were performed in ISR
and the BT proﬁles of CLP mice (Supplementary Figure 1)
were compared to the main CLP survival study (experiment
1). The third CLP run (i.e., experiment 3) showed nearly
an identical BT proﬁle to experiment 1 and was extended to
reach the total n = 28.
2.4.2. Treatment. All animals (total of n = 90 in experiment
1; n = 24 in experiment 2; and n = 28 in experiment 3;
detailed n/group distribution in legends to ﬁgures) were
randomly assigned to receive (in a blinded manner) either
SkQ1 (5 nmol/kg), MitoTEMPO (50 nmol/kg), or placebo
treatment (saline) via intraperitoneal injection at maximally
ﬁve subsequent time points (i.e., 1, 12, 24, 36, and 48 h)
post-CLP (see Figure 9 scheme for detailed description of
experimental groups). For SkQ1, this amounts to
0.0062mg/kg/d for the ﬁrst two days and 0.0031mg/kg/d
for the third day. For MitoTEMPO, this amounts to
0.051mg/kg/d for the ﬁrst two days and 0.0255mg/kg/d
for the third day.
For all experiments, SkQ1/MitoTEMPO was dissolved in
ethanol (96%) and diluted in saline in further steps. Freshly
prepared dilutions were divided into aliquots (one for each
treatment time point separately) and stored frozen at −80°C
protected from light until use. The presence of SkQ1/Mito-
TEMPO molecules was veriﬁed on the ﬁrst and the last days
of experiments. The concentration of SkQ1 was tested spec-
trophotometrically as described in Antonenko et al. 2008
[30]. MitoTEMPO was measured with electron spin reso-
nance spectroscopy as previously described [47].
We elected to administer the ﬁrst antioxidant dose 1 h
post-CLP to approach clinical relevance. We treated mice
over the period of 48 h post-CLP given that it directly
precedes/overlaps with the period of the most robust
mortality in the acute CLP phase [48, 49]. Our treatment
scheme is consistent with the one employed by Plotnikov
et al. [13]. The selected antioxidant concentrations were
adopted from Weidinger et al. [50]. Given that the eﬀects
of SkQ1 were predominantly examined in rats, we have
compared the eﬀects of increasing SkQ1 concentrations
on the respiratory activity of mitochondria in liver homoge-
nates from rats and mice. This was done to ensure that we
remain within the nontoxic range of SkQ1 concentrations
(Supplementary Figure 2).
In the follow-up experiments 2 and 3, SkQ1 (or placebo)
was tested given that only SkQ1 treatment signiﬁcantly exac-
erbated mortality in experiment 1. In experiment 2, mice
received four injections (the last at 36 h post-CLP) and were
sacriﬁced for peritoneal lavage and spleen collection. In
experiment 3, mice received three injections (the last at
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Figure 1: 28-day survival of SkQ1-, MitoTEMPO-, and placebo-
treated control mice. Mortality of treated and placebo mice
subjected to CLP sepsis. Number of mice in each group listed in
the legend (in brackets). SkQ1 versus control: ∗p = 0 03;
MitoTEMPO versus control: p = 0 24.
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24 h post-CLP) and were sacriﬁced to collect the liver for
mitophagy assessment (Figure 9 scheme). Irrespective of
sacriﬁce, the identical protocol for treatment and sampling
procedures was used in experiment 1 and both follow-up
experiments 2 and 3.
Of note, in experiment 2, to generate Figure 6(a), septic
mice were compared using the above-described M-CASS-
like criteria, that is, using our custom-developed scoring
system and BT monitoring; we retrospectively assigned mice
into either predicted-to-die (P-DIE; inner BT≤ 28°C) or
predicted-to-survive (P-SUR; inner BT≥ 35°C) group. For
maximally conservative approach, all mice featured in
Figure 6(a) met the objective [41] BT cut-oﬀ criteria (i.e.,
mice meeting the euthanasia threshold based solely on the
clinical assessment≥ 8 points were not included).
2.5. Blood Sampling. Repeated low-volume blood sampling
was used in all groups reducing the total number of mice
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Figure 2: Comparison of circulating cytokines between SkQ1-, MitoTEMPO-, and placebo-treated control mice. (a–g) Plasma levels of
TNF-α, IL-1β, IL-5, IL-6, IL-10, IL-12p70, and IFN-γ in treated mice (SkQ1 or MitoTEMPO) at 6, 24, 48, and 72 h post-CLP were compared
to the placebo group (CLP +NaCl). For (a–g): at 6 h: control n≥ 19, SkQ1 n = 19, MitoTEMPO n = 19; at 24 h: control n = 19, SkQ1 n = 17,
MitoTEMPO n = 15; at 48 h: control n = 13, SkQ1 n = 12, MitoTEMPO n = 10; at 72 h: control n = 13, SkQ1 n = 11, MitoTEMPO n = 9. Data
points shown as mean± SEM. The exemplary IL-10 inset depicts scatter plot of all groups at 6 h post-CLP time point. 2 k (for brevity)
corresponds to 2000 pg/ml.
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needed for the study [51]. Blood was collected immediately
before CLP (baseline) and at 6, 24, 48, and 72h thereafter
in experiment 1 and for shorter periods (depending on
the sacriﬁce time point) in experiments 2 and 3 (Figure 9
scheme).
Speciﬁcally, 30μl of blood was drawn by puncturing the
facial vein (vena submandibularis) with a 23 gauge needle.
Samples were then collected with a pipette rinsed with ethyl-
enediaminetetraacetic acid (K3-EDTA) (diluted 1 : 50) and
immediately diluted 1 : 10 in PBS. After centrifugation
(1000×g, 5min, 22°C), 270μl of plasma was removed and
stored at −80°C until further analysis.
2.6. Abdominal Lavage. In experiment 2, after sacriﬁce
(isoﬂurane anesthesia followed by cervical dislocation), we
performed abdominal lavages with 5ml cold PBS/3% fetal
calf serum, using an adapted protocol from Ray and Dittel
[52]. The collected cell suspension was deposited in tubes
and kept on ice until further FACS analysis.
2.7. Complete Blood Count. After plasma was removed,
we resuspended the remaining blood pellet with 180μl
Cell-Dyn buﬀer with EDTA and a complete blood count
with diﬀerential (erythrocytes, hemoglobin, platelets, white
blood cells, neutrophil granulocytes, and lymphocytes)
was performed with a Cell-Dyn 3700 counter (Abbott
Laboratories, Illinois, USA) as previously described [51].
2.8. Cytokine and Chemokine Measurement. Interleukin (IL)-
1β, IL-5, IL-6, IL-10, and IL-12p70, interferon (IFN)-γ,
tumor necrosis factor (TNF)-α, macrophage inﬂammatory
protein (MIP)-1α, chemokine ligand (KC; CXCL-1), and
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Figure 3: Comparison of circulating chemokines between SkQ1-, MitoTEMPO-, and placebo-treated control mice. (a–c) Plasma levels of
CXCL1, MCP-1, and MIP-1α in treated mice (SkQ1 or MitoTEMPO) at 6, 24, 48, and 72 h post-CLP were compared to the placebo group
(CLP+NaCl). For (a–c): at 6 h: control n = 19, SkQ1 n = 19, MitoTEMPO n = 19; at 24 h: control n = 19, SkQ1 n = 17, MitoTEMPO
n = 15; at 48 h: control n = 13, SkQ1 n = 12, MitoTEMPO n = 10; at 72 h: control n = 13, SkQ1 n = 11, MitoTEMPO n = 9. Data points
shown as mean± SEM.
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monocyte chemoattractant protein-1 (MCP-1) were analyzed
from plasma samples according to the manufacturer’s proto-
col using FlowCytomix™Multiplex Kits (eBioscience, USA).
2.9. Metabolic and Organ Function/Cell Injury. Plasma levels
of urea, glucose, lactate dehydrogenase (LDH), and alanine
transaminase (ALT) were analyzed with Cobas c111 analyzer
(Roche, Switzerland). The lower detection limit for urea
was 3mg/dL, for glucose 1.98mg/dL, for LDH 10U/L, and
for ALT 2U/L. The inner body temperature was measured
(at least twice per 24 h) using a Fluke 52 Series II thermome-
ter (Fluke, USA) with a rectal probe.
2.10. Nitrate/Nitrite (NOx) Measurement. The Nitric Oxide
Analyzer (NOA) (Nitric Oxide Analyzer Sievers 280i, GE
Analytical Instruments, USA) consisted of a glassware system
and an electronic detection unit. Plasma sampleswere injected
through a septum into the glass vessel, where NO species were
converted selectively to NO(g) by a redox active reagent (VCl3
for total NO). Following the reduction step, NOmolecules are
carried to the reaction chamber of the detection unit byN2, an
inert gas which was constantly purged through the mixture
during measurements. Inside the reaction chamber, NO from
the gas phase reacted rapidly with O3 to form NO2
∗ in an
excited state (NO +O3→NO∗2 + O2). As the excited e−
returned to its ground state, a photon was emitted and
detected as chemiluminescence (hv) (NO∗2 →NO2 + hv).
Emitted lightwas detected and ampliﬁed by a photomultiplier
tube (PMT) to generate an electric signal. The detection limit
for NO and related species in liquid samples was ~1 pmol.
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Figure 4: Comparison of organ function parameters between SkQ1-, MitoTEMPO-, and placebo-treated control mice. Plasma levels of
treated mice (SkQ1 or MitoTEMPO) of (a) urea, (b) ALT, (c) glucose, and (d) LDH in mice at baseline and post-CLP were compared to
the control group (CLP + placebo). For (a–d): at BL n = 20; at 6 h control n = 20, SkQ1 n = 19, MitoTEMPO n = 19; at 24 h control n = 19,
SkQ1 n = 17, MitoTEMPO n = 17; at 48 h control n = 13, SkQ1 n = 12, MitoTEMPO n = 10; at 72 h control n = 13, SkQ1 n = 11,
MitoTEMPO n = 9. Data points shown as mean± SEM.
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2.11. Flow Cytometry. Peritoneal lavage ﬂuid samples were
kept in 50ml Falcon tubes on ice and were processed within
1 hour of collection. After red blood cell lysis, the cell suspen-
sion was ﬁltered through a 70μM cell strainer (BD, Bedford,
MA, USA) to singularize the cells, washed with PBS, and
adjusted to the recommended cell count for staining. A total
of 100μL of the suspension was then transferred to FACS
tubes (Beckman Coulter, Brea, CA, USA) and incubated with
ﬂuorophore-conjugated antibodies on ice for 30min. If not
indicated otherwise, all antibodies were purchased from
eBioscience (Vienna, Austria). Leukocyte subsets in the
lavage ﬂuid were identiﬁed by morphology and the positiv-
ity/negativity for the following antigens: presence of the
integrin subunit CD11b (-FITC conjugate) and the granulo-
cyte cell surface determinant Ly6-G (Gr-1, APC-conjugate)
as well as the absence of the macrophage adhesion receptor
F4-80 (PE-conjugate) was used to determine neutrophil pop-
ulations. CD11b/F4-80-positive and Ly6-G-negative subsets
were identiﬁed as macrophages. Cell suspensions were
washed with PBS and were measured on a FC-500 ﬂow
cytometer (Beckman Coulter, Brea, CA, USA). A minimum
of 1× 10E4 intact cells were recorded and analyzed in FlowJo
software (FlowJo LLC., Ashland, Oregon); Leukocyte subsets
were displayed as % of intact cells.
2.12. Bacterial Growth Assessment. The spleens were
obtained immediately after sacriﬁce under sterile conditions
following the protocol of Barquero-Calvo et al. [53] allowing
small modiﬁcations. We used nine parts of PBS containing
0.1% Tween 20 per g of spleen (dilution 1 : 10), assuming that
the volume of 1 g of spleen corresponds to 1ml of PBS (e.g.,
0.5 g of spleen and 4.5ml of PBS 0.1% Tween 20). Isolated
spleens were homogenized using pellet pestles (Dstroy-S-
15, Biozym, Oldendorf). After centrifugation at 13000 rpm
for 10 minutes, supernatant was removed and serially diluted
with PBS for subsequent plating on lysogeny broth (LB) agar
plates (Miller, USA) and incubation overnight at 37°C.
Colony-forming units were counted after 24 h.
2.13. Western Blotting. Mice were euthanized at 24h post-
CLP, and liver samples were immediately snap-frozen in
liquid nitrogen and stored at −80°C for further analysis. All
analyses were performed in Jena University Hospital
(Germany). Total protein content was isolated from the
frozen tissue samples by a protein isolation buﬀer pH7.5
(10mM Tris, 250mM saccharose, 1mM EDTA, 1%
phosphatase-inhibitor cocktail, and 1% protease inhibitor 2)
using a dounce homogenizer (Kimble Chase, Mexico).
Homogenates were centrifuged at 900g for 10min at 4°C
to obtain the post nucleus fraction, followed by 100,000g
for 1 h at 4°C to separate the cytosolic and microsomal frac-
tions. Protein content in the post nucleus supernatant was
determined using the bicinchoninic acid (BCA) assay (Sigma
Aldrich, Hamburg, Germany). Fractions were used as indi-
cated. 20 µg protein was loaded on a sodium dodecyl sulfate
(SDS) gel and transferred to a polyvinylidenﬂuorid (PVDF)-
membrane (Roth, Karlsruhe, Germany). Membranes were
incubated with 5% N,O-bis(trimethylsilyl)acetamid (BSA)
or skim milk (Sigma-Aldrich, Hamburg, Germany) in
tris-buﬀered saline with Tween20 (TBST) for 1 h at room
temperature. Primary antibodies in 5%BSAor skimmilkwere
incubated on a shaker overnight at 4°C. Horseradish peroxi-
dase (HRP)-conjugated secondary antibodies (1 : 5000) were
incubated for 1 hour at room temperature. The following pri-
mary antibodies were used: anti-LC3B, TOM20, cytochrome
C (Cell Signaling Technology®, Danvers, USA), and p62 or
anti-β-actin (Abcam®, Cambridge, UK). Detection of the sec-
ondary antibody by chemiluminescence was performed using
HRP substrate (Immobilon Western HRP Substrat, Merck
Millipore,Darmstadt, Germany) by the LAS3000 (GEHealth-
care, Frankfurt, Germany). Protein content was quantiﬁed
using software ImageJ (National Institutes of Health,
Bethesda, MD, USA). β-Actin or Coomassie-stained gel
served as loading control to calculate the diﬀerences in the
protein expression between the groups. To quantify the level
of autophagy, the LC3B-II : LC3B-I ratio was calculated based
on a densitometric analysis and normalized to β-actin.
2.14. Statistical Analysis. The Kaplan-Meier method was used
to plot and compare the 28-day survival in experiment 1.
All other data sets were tested for normality before further
analysis. Abnormally distributed data sets were log-
transformed to achieve normal distribution. Comparisons
among the three groups were made using one-way
ANOVA and Bonferroni’s Multiple Comparison Test for
the parametric data and Kruskal-Wallis Test and Dunn’s
Multiple Comparison Test for the nonparametric data.
To compare the SkQ1 with the placebo group, we used
the unpaired Student t-test for parameters with parametric
distribution or the Mann–Whitney Test for parameters
with nonparametric distribution. The level of signiﬁcance
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Figure 5: NOx concentration in the blood plasma. All forms of
NO (NOx) in plasma were measured at BL (0 h), 6, 24, 48, and
72 h post-CLP. At BL: control n = 20, SkQ1 n = 20, MitoTEMPO
n = 20; at 6 h: control n = 20, SkQ1 n = 19, MitoTEMPO n = 19; at
24 h: control n = 19, SkQ1 n = 17, MitoTEMPO n = 15; at 48 h:
control n = 13, SkQ1 n = 12, MitoTEMPO n = 10; at 72 h: control
n = 13, SkQ1 n = 11, MitoTEMPO n = 9. Data points shown as
mean± SEM. The inset depicts scatter plot of all groups at 24 h
post-CLP time point.
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was set at p < 0 05. All statistical analyses and graphs were
made with GraphPad (San Diego, USA).
3. Results
3.1. Application of Mitochondrial ROS Scavengers
Exacerbated Mortality. Survival was monitored for 28 days
post-CLP. To be consistent with clinical severity of abdomi-
nal sepsis, mice were subjected to a medium-severe CLP with
38% mortality (average of six CLP repetitions). Neither
MitoTEMPO nor SkQ1 exerted a protracted survival ben-
eﬁt. Conversely, SkQ1 treatment exacerbated mortality to
67% (p = 0 03) by day 28 (Figure 1). This negative eﬀect
was consistent in all six CLP repetitions (Supplementary
Figure 3); it was apparent immediately in the acute phase
(i.e., within 1–5 days post-CLP; in four CLP repetitions)
and continued into the chronic phase until the end of the
observation period. MitoTEMPO eﬀect was inconsistent
among individual repetitions (not shown) and did not reach
statistical signiﬁcance (p = 0 24; Figure 1).
3.2. Application of Mitochondrial ROS Scavengers Did Not
Modulate the Inﬂammatory Response to Polymicrobial Sepsis.
We examined a comprehensive set of circulating cytokines
that are typically upregulated in both human andmouse sepsis
[54, 55]. In general, CLP induced an increase of all cytokines
measured; the strongest concentration was recorded for
IL-6, MCP-1, CXCL-1, and MIP-1α at 24 h (Figures 2
and 3). None of those post-CLP increases was further sig-
niﬁcantly modiﬁed by either SkQ1 or MitoTEMPO.
Following acute sepsis, a strong rearrangement of cell pop-
ulations occurs. We found out that neither SkQ1 nor Mito-
TEMPO aﬀected the CLP-induced lymphopenia (at 24 h:
placebo 1.2 pg/ml versus SkQ1 1.1 pg/ml versus MitoTEMPO
0.9 pg/ml) and neutrophilia (at 24 h: placebo 0.4 pg/ml versus
SkQ1 0.4 pg/ml versus MitoTEMPO 0.3 pg/ml) when com-
pared to the placebo group (Supplementary Figure 5).
3.3. Application of Mitochondrial ROS Scavengers Did Not
Change Organ Function/Injury and Metabolic Parameters.
Functional tissue damages are hallmarks of sepsis
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Figure 6: Bacterial load in the spleen. Number of colony-forming units (CFUs) per ml spleen homogenate. (a) Mice that were
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the body temperature recordings taken before sacriﬁce time point at 48 h post-CLP. (b) Placebo-treated (n = 7) versus SkQ1-groups
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Flow cytometry determination of macrophages and neutrophils, displayed as percent of intact measured cells. Placebo n = 7, SkQ1 n = 9. Data
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pathogenesis [9]. We followed temporal ﬂuctuations of glu-
cose (GLU), alanine aminotransferase (ALT), lactate dehy-
drogenase (LDH), and urea in septic mice after CLP. In
general, all groups displayed similar trajectories at all time
points (Figure 4). Speciﬁcally, ALT, LDH, and urea peaked
in all treatment groups at 24 h (ALT: placebo 111U/l versus
SkQ1 119U/l versus MitoTEMPO 115U/l; LDH: placebo
940U/l versus SkQ1 1097U/l versus MitoTEMPO 773U/l;
urea: placebo 89mg/dl versus SkQ1 97mg/dl versus Mito-
TEMPO 93mg/dl), while blood glucose decreased by
approx. 63% (BL: 128mg/dl versus 24 h: 49mg/dl) in the pla-
cebo group. Hypoglycemia persisted until 72 h post-CLP
(placebo 68mg/dl versus SkQ1 64mg/dl versus MitoTEMPO
76mg/dl), while the other parameters recovered.
3.4. Application of Mitochondrial ROS Scavengers Did Not
Aﬀect NOx Concentration in Plasma. Nitric oxide (NO)
and its metabolized forms nitrite (NO2
−) and nitrate
(NO3
−; both referred to as NOx) play a central role in
inﬂammation and correlate with severity of sepsis. We
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Figure 8: Comparison of mitophagy and mitochondrial integrity in the liver of placebo-treated control versus SkQ1-treated groups at 24 h
post-CLP. CLP mice received a total of three SkQ1/placebo injections before sacriﬁce at 24 h. All panels display densitometric analysis of
the Western blot assay as well as representative Western blots. (a) LC3-II-to-LC3-I ratio (normalized to actin), (b) p62 (normalized
to total protein), and (c) cytosolic TOM-20 release (normalized to actin). Total number of CLP mice loaded on three diﬀerent gels:
SkQ1 n = 16; control (placebo) n = 12. Data as (min–max) box-and-whiskers plots. Dotted lines indicate upper/lower standard
deviation calculated based on eight healthy control mice (no CLP, no treatment) that were analyzed together with the CLP mice.
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Figure 9: Schematic illustration of treatment, blood/tissue sampling, and monitoring. The entire study was divided into three experimental
parts that followed the same treatment protocol with speciﬁc modiﬁcations described below and depicted graphically in the ﬁgure. 3-month-
old female mice were subjected to polymicrobial CLP sepsis. Mice were subjected to low-volume repetitive blood sampling (30 μl blood
volume/sampling; time points indicated by a single blood drop) maximally ﬁve times: At baseline (BL, immediately before CLP) 6 h, 24 h,
48 h, and 72 h post-CLP. Maximally, ﬁve intraperitoneal injections with either SkQ1, MitoTEMPO, or placebo treatment were conducted
at 1 h, 12 h, 24 h, 36 h, and 48 h post-CLP (indicated by syringes). In experiment 1: mice (n = 90) were monitored for 28 days (all ﬁve
blood collections and treatment injections performed). In experiment 2: mice (n = 24) were sacriﬁced at 48 h post-CLP (four blood
collections and treatment injections performed). In experiment 3: mice (n = 28) were sacriﬁced at 24 h post-CLP (three blood collections
and treatment injections performed). White block arrows indicate sacriﬁce time point for experiments 2 and 3.
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measured NOx concentration in plasma at BL, 6, 24, 48,
and 72 h post-CLP (Figure 5); there were no signiﬁcant inter-
group NOx changes. Similar to the organ function parame-
ters, NOx peaked at 24 h post-CLP (approx. 4-fold higher
than baseline).
3.5. SkQ1 Treatment Did Not Impair the Bacterial Clearance
in the Spleen. Because of the consistent survival deterioration
after SkQ1 (but not MitoTEMPO), we only compared the
SkQ1 and placebo groups in experiment 2. First, to verify
the bacterial clearance, we determined colony-forming units
(CFUs) in the spleen homogenates. Mice that were predicted
to die post-CLP had approximately 100-fold more CFUs in
the spleen than mice that were predicted to survive CLP
(Figure 6(a); p = 0 03). However, this eﬀect was not related
to antioxidant treatment (Figure 6(b)).
3.6. SkQ1 Treatment Did Not Change Macrophage or
Granulocyte Counts from Peritoneal Lavages. In experiment
2, to identify potential treatment-related diﬀerences in the
abdominal leukocyte populations, we performed peritoneal
lavages at 48 h post-CLP and analyzed cells by FACS. In gen-
eral, the cell counts were similar between both groups
(Figures 7(a) and 7(b)): macrophages (CD11b+/F4/80+)
reached 11% in placebo and 16% in SkQ1, while granulocytes
(Ly6G+) reached 56% in placebo and 45% in SkQ1.
3.7. SkQ1 Treatment Did Not Modify the Mitochondrial
Autophagy. Finally, we investigated mitophagy and integrity
of mitochondria in the liver (as a relatively sensitive organ)
to establish whether SkQ1 exerted a direct detrimental eﬀect
upon this organelle. Western blot analysis of key proteins
involved in autophagy (i.e., LC3B, p62) [56], mitochondrial
membrane integrity (i.e., TOM20; Figures 8(a), 8(b), and
8(c)), and apoptosis (i.e., cytochrome C; Supplementary
Figure 5) was performed. Compared to CLP mice treated
with placebo, SkQ1 failed to reveal any modulation in the
expression of those markers in the liver at 24 h post-CLP.
This implies that the SkQ1-induced exacerbation of CLP
mortality was not caused by direct mitochondrial damage.
4. Discussion
Recently, Sepsis-3 guidelines redeﬁned sepsis as a “life-
threatening organ dysfunction caused by a dysregulated host
response to infection” [1]. ROS production/release is thought
to play a major part in the progression of organ failure and
mitochondrial dysfunction [12, 57]. Therefore, we aimed to
improve the outcome of mice with polymicrobial sepsis by
selectively inhibiting ROS at one of its key formation sites,
the mitochondrion. Surprisingly, none of the tested antioxi-
dants demonstrated any beneﬁts, while SkQ1 markedly
increased CLP mortality.
Best to our knowledge, this is the only study demonstrat-
ing a negative long-term impact of targeted mitochondrial
antioxidant scavenging (i.e., by SkQ1) upon abdominal sepsis
survival. The majority of rodent studies showed beneﬁts of
SkQ1 and/or MitoTEMPO in acute inﬂammatory conditions
including pyelonephritis [13], gastritis [58], cardiomyopathy
[31], SIRS [59], and sepsis [35]. Similar was true in a rat
model of pneumosepsis [60] and endotoxemia [14]. Antiox-
idant (not mitochondria targeted) treatment did not improve
survival only in three mouse studies, acute pancreatitis [61],
pancreatic cancer [62], and CLP [63] models. While surpris-
ing, our protracted study design (Supplementary Figure 3)
allows postulating that the reduction of survival due to
SkQ1 was not a coincidental observation.
First, we examined two main elements of the systemic
CLP response, inﬂammation, and organ function, to discern
the deleterious mechanism(s). We repeatedly measured over
twenty relevant parameters in mice enrolled in the survival
study. This ensured maximal synchrony between the end-
outcome eﬀect and detection of a potential mechanism-of-
action. CLP-induced dysregulation of the inﬂammatory and
organ function system was consistent with data reported by
us [64, 65] and others [66]. Surprisingly, we failed to observe
any additional consistent changes caused by the SkQ1 and/or
MitoTEMPO. This is suggestive of two things. First, the
increased mortality in the SkQ1 mice did not appear to be
caused by an evidently exacerbated early systemic inﬂamma-
tory response, especially given that the four-day cytokine
trajectories preceded/overlaid with the period of the highest
acute mortality (days 1–3 post-CLP). Second, hepatocyte
damage and/or impaired kidney function as well as dysregu-
lation of carbohydrate metabolism was not a culprit either.
The latter, however, does not exclude potential late derange-
ments occurring in those and other organs (e.g., heart, lungs,
and intestines) and/or systems (e.g., microcirculation, coagu-
lation) that we did not examine. The protracted readout of
the CLP-induced NOx ﬂuctuations in the blood was consis-
tent with the above changes. Similar to other works [67],
the post-CLP peak of circulating nitrate/nitrite occurred in
our study at 24h time point but it was not further modiﬁed
by antioxidants.
Next, we tested whether SkQ1 modulated the abdominal
cellular characteristics and/or impeded bacterial clearance.
We performed two-tier retrospective comparison: (1) treat-
ment versus control as well as (2) predicted-to-die versus
predicted-to-live using the body temperature-based predic-
tion of outcome [41]. Such an approach allows more precise
veriﬁcation of the potential treatment eﬀect upon the lethal
phenotype. Our data show that compared to (predicted-to-
be) survivors, predicted-to-die mice had much more pro-
nounced bacterial load in the spleen. Yet again, the placebo
treatment comparison revealed that SkQ1 neither altered
the abdominal recruitment of phagocytes nor interfered with
the bacterial clearance.
Impaired mitochondrial function was not always
detected in CLP models, particularly in rodents [68]. Yet,
the absence of a visible mitochondrial dysfunction in such
cases was explained by activation of the eﬀective autophagy
process and removal of nonfunctional mitochondria. Thus,
the autophagy appeared to us as a very sensitive sensor of
the potential impairment of mitochondrial function. The
ﬁnal experiment 3 showed, however, that SkQ1 treatment
was not by itself harmful to mitochondria (in the liver)
given that neither autophagy (i.e., mitophagy) nor mito-
chondrial membrane integrity was altered by SkQ1 at the
administered dose. This is in line with the nontoxicity
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assessment of SkQ1 in liver homogenates of healthy mice
and rats (Supplementary Figure 2).
This leaves us with a negative eﬀect of SkQ1 upon sepsis
survival and insuﬃcient understanding what this eﬀect can
be attributed to. There are several ways to explain the absence
of the expected antioxidant beneﬁts as well as the uncertain
mechanism-of-action behind the worsened mortality. First,
a proper dose ﬁne tuning of the antioxidants appears impor-
tant. For example, at micromolar concentrations, cationic
quinone derivatives have a strong pro- not antioxidant eﬀect
[29]. Thus, it is unlikely that a higher dose would have less-
ened (reversed) the observed adverse SkQ1 eﬀect. We rather
consider inapt treatment timing and/or relatively low-risk-
of-death sepsis CLP cohort as culprits. Speciﬁcally, we used
a repeated treatment to cover the ﬁrst two post-CLP days,
the phase with the most frequent acute sepsis mortality. It
seems now that such a blanket coverage might have been
too aggressive and/or wide ranging, especially in a nonoverly
lethal sepsis environment of our study. A minimal threshold
of mitochondrial ROS (mtROS) is key for maintaining intra-
cellular defense signaling pathways [69, 70] to enable, for
example, a proper response to bacterial invasion [71].
Although we did not see a post-SkQ1 exacerbation of
microbial load in the spleen, a complete blockage of mtROS
(not detrimental to mitochondria themselves) could have
impeded bacterial clearance at other sites. Likewise, blanket
mtROS scavenging could have deregulated transcription of
protective hypoxia inducible factors [72, 73] that we did not
examine. Of note, there is an emerging role of cell-free hemo-
globin in sepsis-induced organ failure [74]. For example, the
recent clinical trial showed that blocking ferryl hemoglobin
with acetaminophen improved sepsis outcome [75]. Thus,
in addition to mtROS, rich amounts of ROS are generated
by diﬀerent intra/extracellular sources such as NADPH-oxi-
dase, myeloperoxidase, and ferryl hemoglobin. Future studies
need to explain precise site- and cell-speciﬁc roles of oxida-
tive stress in sepsis. Of note, recent antioxidant treatment
using N-acetylcystein and butylated hydroxyanisole (unspe-
ciﬁc ROS scavengers) improved survival of mice with speciﬁc
deletion of the iron sequestering protein ferritin heavy chain
(FTH); restoration of hepatic glucose production was identi-
ﬁed as the key mechanism of this beneﬁt [76]. Given that our
CLP mice did not enter a prolonged (potentially deadly)
hypoglycemia, this beneﬁcial eﬀect would not have applied.
The two recent sepsis studies oﬀer some relevant clues
regarding the antioxidant treatment timing/dosage and
model severity [13, 63]. At ﬁrst, CLP mice were given a
single-bolus coenzyme Q10 (strong mitochondria-targeted
antioxidant) at 5 h and 20h post-CLP. Only the latter
attenuated organ injury and (insigniﬁcantly) improved
survival [58]. The authors also noted that when sham (also
control) mice were treated with coenzyme Q10, their
injury score doubled (versus untreated sham/control) and
a (statistically insigniﬁcant) decline in survival occurred
in sham+ coenzyme Q10 mice. This indicates a predilection
for detrimental eﬀects of coenzyme Q10 in a nonlethal
milieu. The second study was performed in rats with acute
pyelonephritis (APN) who beneﬁted from SkQR1 (we repro-
duced their treatment protocol) [13]. There are four major
diﬀerences between that study and ours: cumulative dosage
(500 versus 25nmol/kg), species (rat versus mouse), origin
of sepsis (urosepsis versus abdominal), and the infection
severity. We consider the latter two elements as essential.
First, the rat APN model displayed approx. 70% while our
model reached a total 40% mortality by day 28. We believe
that treatment beneﬁts are much more likely to occur in a
lethal versus moderate severity. For example, inhibition of
murine leukotriene B4 synthesis improved CLP survival
in severe sepsis [77], while the same agent worsened sur-
vival by 50% in a sublethal CLP [78]. We recently showed
that only CLP mice predicted-to-die beneﬁted from dexa-
methasone [49], whereas PAI-1 inhibition exacerbated CLP
mortality in mice that were predicted to survive [79]. A
similar response scenario cannot be ruled out in our study
given that on average surviving mice outweighed those
with the lethal CLP phenotype as opposed to the (beneﬁ-
cial) coenzyme Q10 treatment (65% mortality) [63], Mito-
TEMPO mouse experiment (60% mortality), and SkQR1
APN rat study [13]. Likewise, in the recent SIRS study, 48 h
pretreatment with SkQ1 improved mouse survival in a lethal
but not in 50% mortality setup [59].
The negative eﬀect of SkQ1 can be also attributed to the
speciﬁcity of CLP; SkQ1 at the identical (pretreatment) dose
was protective in the LPS rat model [50]. CLP only repro-
duces polymicrobial human sepsis of abdominal origin, and
it cannot be reﬂexively extended to other sepsis types [2].
SkQ1 was never tested in CLP, and it is plausible that its neg-
ative eﬀects may arise only in sepsis originating from this
particular body compartment. Of note, our study monitored
survival for 28 days. Although advised in preclinical sepsis
[2], a protracted followup has never been tested before for
targeted antioxidant treatment in sepsis. Had we used a 7-
day observation, the SkQ1-induced eﬀect would have been
statistically insigniﬁcant.
There are several limitations in our study. First, only pla-
cebo versus verum CLP mice were compared and sham con-
trols were not employed. Second, we did not assess the
mitochondria-and/or cell-derived ROS. Third, mitophagy
assessment was limited to a single (i.e., 24 h post-CLP) time
point. Finally, CLP experiments were performed at two dif-
ferent locations (i.e., LBI and ISR) and the potential inﬂuence
of macrobiome ﬂuctuations was not veriﬁed.
It is also possible that the rodent CLP model is not an
appropriate testing model for antioxidant therapies given
the overall higher resistance of rodents to trauma/infection
[2] and the qualitative diﬀerence in ROS release [80] under
infectious and/or endotoxic stimuli (rodents versus humans).
Thus, the sudden ROS release might not be as damaging in
septic rodents as it is in patients. Long-term mouse studies
using pneumosepsis, CASP, and candidiasis models as well
as testing the mitochondria-speciﬁc antioxidants in various
sepsis severity protocols will verify whether the negative
eﬀect observed here can be attributed to the CLP model itself,
species used, the magnitude of the sepsis insult, or combina-
tion thereof. Finally, our study can be also considered as
cautionary; it suggests that in certain severe inﬂammatory
states, mtROS scavenging can be therapeutically ineﬃcient
and/or deleterious.
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